Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens

Neurosurgery

Volumn 45, Issue 6, 1999, Pages 1442-1453

  Feldkamp, Matthias M ^a,b   Lala, Prateek ^a   Lau, Nelson ^a   Roncari, Luba ^a   Guha, Abhijit ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Astrocytoma; EGFRvIII; Epidermal growth factor receptor; Glioblastoma multiforme; Glioma; Mitogen activated protein kinase; Ras; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032763824     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199912000-00034     Document Type: Article

References (57)

1. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/ neu-overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998.
2. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996.
3. Bigner SH, Burger PC, Wong AJ, Werner MH, Hamilton SR, Muhlbaier LH, Vogelstein B, Bigner DD: Gene amplification in malignant human gliomas: Clinical and histopathologic aspects. J Neuropathol Exp Neurol 47:191-205, 1988.
4. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50:8017-8022, 1990.
5. Bos JL: Ras oncogenes in human cancers: A review. Cancer Res 49:4682-4689, 1989.
6. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ: JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037, 1994.
7. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, James CD: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9:2313-2320, 1994.
8. Fenstermaker RA, Ciesielski MJ, Castiglia GJ: Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells. Oncogene 16:3435-3443, 1998.
9. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, Bigner DD, Weiner LM: Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53:3217-3220, 1993.
10. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD: Expression of PDGF and PDGF receptors in human astrocytoma operative specimens supports the existence of an autocrine loop. Int J Cancer 60:168-173, 1995.
11. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15:2755-2765, 1997.
12. Guha A, Gowacka D, Carrol R, Dashner K, Black PM, Stiles CD: Expression of platelet derived growth factor and platelet derived growth factor receptor mRNA in a glioblastoma from a patient with Li-Fraumeni syndrome. J Neurol Neurosurg Psychiatry 58: 711-714, 1995.
13. Guha A, Lau N, Gutmann D, Provias J, Pawson T, Boss G: Ras-GTP levels are elevated in human NF1 peripheral nerve tumours. Oncogene 12:507-513, 1996.
14. Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJS: Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 56:3859-3861, 1996.
15. Hills D, Rowlinson-Busza G, Gullick WJ: Specific targeting of a mutant, activated EGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 63:537-543, 1995.
16. Huang HJS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272:2927-2935, 1997.
17. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 87:4207-4211, 1990.
18. Kleihues P, Burger P, Scheithauer B: Histological Typing of Tumors of the Nervous System. Berlin, Springer-Verlag, 1991.
19. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN: A putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947, 1997.
20. Libermann TA, Razon N, Bantal AD, Yarden Y, Schlessinger J, Soreq H: Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 44:753-760, 1984.
21. Louis DN: The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11-21, 1994.
22. Louis DN, Gusella JF: A tiger behind many doors: Multiple genetic pathways to malignant glioma. Trends Genet 11:412-415, 1995.
23. Marshall CJ: Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185, 1995.
24. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A, Poustka A: DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 17:32-39, 1997.
25. Montgomery RB, Moscatello DK, Wong AJ, Cooper JA, Stahl WL: Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 270:30562-30566, 1995.
26. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539, 1995.
27. Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ: Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13:85-96, 1996.
28. Moscatello DK, Ramirez G, Wong AJ: A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 57:1419-1424, 1997.
29. Nagane M, Coufal F, Lin H, Bögler O, Cavenee WK, Huang HJ: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086, 1996.
30. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee' WK, Su Huang HJ: Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res 55:1941-1945, 1995.
31. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ: A mutant epidermal growth factor receptor common in human gliomas confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91:7727-7731, 1994.
32. Okamoto S, Yoshikawa K, Obata Y, Shibuya M, Aoki S, Yoshida J, Takahashi T: Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor. Br J Cancer 73:1366-1372, 1996.
33. Olson JJ, Barnett D, Yang J, Assietti R, Cotsonis G, James CD: Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 4:215-222, 1998.
34. O'Rourke DM, Nute EJ, Davis JG, Wu C, Lee A, Murali R, Zhang HT, Qian X, Kao CC, Greene MI: Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: Implications for subdomain contributions to receptor assembly. Oncogene 16:1197-1207, 1998.
35. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998.
36. Plate KH, Breier G, Welch HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848, 1992.
37. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993.
38. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HS: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271:25639-25645, 1996.
39. Ramirez G, Moscatello DK, Palazzo J, Peraza S, Wong AJ: Expression of a variant epidermal growth factor receptor in Barrett's esophagus and gastric adenocarcinoma. Proc Am Assoc Cancer Res 38:277, 1997 (abstr).
40. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736-2739, 1993.
41. Reist CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR: Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 57:1510-1515, 1997.
42. Reist CJ, Batra SK, Pegram CN, Bigner DD, Zalutsky MR: In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: Comparison with its murine parent. Nucl Med Biol 24:639-647, 1997.
43. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532, 1994.
44. Scheele JS, Rhee JM, Boss GR: Determination of absolute amounts of Ras-GDP and GTP bound to Ras in mammalian cells: Comparison of parental and Ras-overproducing NIH 3T3 fibroblasts. Proc Natl Acad Sci U S A 92:1097-1100, 1994.
45. Schmidt M, Reiser P, Hills D, Gullick WJ, Wels W: Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF receptor-specific antibody-toxin. Int J Cancer 75:878-884, 1998.
46. Shamah SM, Stiles CD, Guha A: Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 13:7203-7212, 1993.
47. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987.
48. Steck PA, Lee P, Hung MC, Yung WK: Expression of an altered epidermal growth factor receptor by human glioblastoma cells. Cancer Res 48:5433-5439, 1988.
49. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362, 1997.
50. Sugawa N, Ekstrand AJ, James CD, Collins VP: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 87:8602-8606, 1990.
51. Trojan J, Blossey BK, Johnson TR, Rudin SD, Tykocinski M, Ilan J, Ilan J: Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci U S A 89:4874-4878, 1992.
52. Tuzi NL, Uenter DJ, Kumar S, Staddon SL, Lemoine NR, Gullick WJ: Expression of growth factor receptors in human brain tumours. Br J Cancer 63:227-233, 1991.
53. Venter D, Bevan K, Ludwig R: Retinoblastoma gene deletions in human glioblastomas. Oncogene 6:445-448, 1991.
54. Walker F, Kato A, Gonez LJ, Hibbs ML, Pouliot N, Levitzki A, Burgess AW: Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation. Mol Cell Biol 18:7192-7204, 1998.
55. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutsky MR, Bigner DD: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-3148, 1995.
56. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969, 1992.
57. Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, Taniguchi S, Shibuya M: Amplification of the structurally and functionally altered epidermal growth factor receptor gene (cerbB) in human brain tumors. Mol Cell Biol 8:1816-1820, 1988.